Table 2. Survival analysis according to diagnostic features of the dogs with lymphoma.
| Variable | Group | NT group | T group | ||||
|---|---|---|---|---|---|---|---|
| n | MST (days) | p-value | n | MST (days) | p-value | ||
| Anatomic | Nonmulticentric | 4 | 59.25 | 0.646 | 6 | 41.20 | 0.000* |
| Multicentric | 26 | 83.37 | 41 | 416.34 | |||
| WHO stage | I | 2 | 187.50 | 0.137 | 0 | 0.957 | |
| II | 1 | 164.00 | 1 | 2.00 | |||
| III | 3 | 133.50 | 4 | 269.80 | |||
| IV | 12 | 33.70 | 19 | 473.83 | |||
| V | 12 | 96.63 | 23 | 289.76 | |||
| WHO substage | a | 10 | 137.57 | 0.056 | 18 | 408.07 | 0.276 |
| b | 20 | 60.44 | 29 | 313.16 | |||
| Immunologic | T cell | 1 | 30.00 | 2 | 39.50 | 0.018* | |
| B cell | 1 | 11.00 | 8 | 475.26 | |||
NT group: no-treatment group; T group: treatment group; MST: mean survival time; WHO: World Health Organization; *: statistically significant.